Search All UT System Experts

A mononuclear cell dose of 3 x 105/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation

R. J. Smith, J. W. Sweetenham

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'A mononuclear cell dose of 3 x 105/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation'. Together they form a unique fingerprint.

Medicine & Life Sciences